NKGN (NKGen Biotech) Additional Paid-In Capital : $130.20 Mil(As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Additional Paid-In Capital?

NKGen Biotech's quarterly additional paid-in capital increased from Mar. 2024 ($122.84 Mil) to Jun. 2024 ($124.59 Mil) and increased from Jun. 2024 ($124.59 Mil) to Sep. 2024 ($130.20 Mil).

NKGen Biotech's annual additional paid-in capital increased from Dec. 2021 ($14.36 Mil) to Dec. 2022 ($80.74 Mil) and increased from Dec. 2022 ($80.74 Mil) to Dec. 2023 ($121.73 Mil).

NKGen Biotech Additional Paid-In Capital Historical Data

The historical data trend for NKGen Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Additional Paid-In Capital Chart

NKGen Biotech Annual Data

Trend

Dec21

Dec22

Dec23

Additional Paid-In Capital

14.36

80.74

121.73

NKGen Biotech Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Additional Paid-In Capital	Get a 7-Day Free Trial					120.80	121.73	122.84	124.59	130.20

NKGen Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

NKGen Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (OTCPK:NKGN) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

3001 Daimler Street, Santa Ana, CA, USA, 92705

Website

https://www.nkgenbiotech.com

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.